The NIH releases whole-genome data from the Alzheimer’s Sequencing Project.
Scientists are tweaking immune pathways to scavenge amyloid and curb symptoms in Alzheimer’s mice.
New research reveals fundamental roles for astrocytes and microglia in shaping neural circuits.
A gene therapy approach to protect cholinergic neurons appeared safe and seemed to stabilize brain metabolism in a Phase 1 trial of AD patients.
The Internet is poised to play a growing role in recruiting for Alzheimer’s clinical trials.
In the early days of tau brain imaging, neurofibrillary pathology appears to match up with the subtle cognitive decline of presymptomatic Alzheimer’s.
New strategies may help find and retain participants for Alzheimer’s trials.
With several microRNAs being overly active in ALS, an antisense therapy to one slows the disease in mice, apparently by reducing neuroinflammation.
Changing ApoE levels in midlife influences Aβ pathology in mice, supporting an ApoE-oriented therapeutic strategy in Alzheimer’s disease.
Researchers propose four stages of TDP-43 pathology based on the spread of the protein through the brain.
Meet ADCS-PACC, C3: Composites that measure subtle changes in cognition appear reliable, clearing the way for their use in clinical trials of people with presymptomatic AD.